Changes of memory B- and T-cell subsets in lupus nephritis patients

Joanna Kosalka*, Bogdan Jakiela*, Jacek Musial

Jagiellonian University Medical College, Department of Medicine, Krakow, Poland

*Both authors have equally contributed to this manuscript

Abstract

Introduction. Renal involvement in systemic lupus erythematosus (SLE) is associated with production of antibodies to double stranded DNA, deposition of immune complexes and organ damage. These processes have been linked with abnormalities in B- and T-cell memory compartments. The aim of the study was to analyze subsets of peripheral memory B-cells and T-cells in lupus nephritis (LN) patients.

Material and methods. We used multicolor flow cytometry to analyze major memory subsets of peripheral blood B-cells (defined by CD27, IgD and CD21) and T-cells (CD45RA, CD45RO, CCR7) in 32 patients with active or inactive LN, and 23 control subjects.

Results. Lupus nephritis patients were characterized by increased percentage of immature/early-transitional B-cells (CD27-IgD+CD21-), higher frequency of activated switched memory (SM, CD27+IgD-CD21-) and exhausted memory B-cells (CD27-IgD-), and decrease in non-switched memory (NSM, CD27+IgD+) B-cells. CD21low subsets (immature and activated B-cells) were particularly expanded in patients with active disease. In both groups of LN patients we observed decline in the absolute count of NSM B-cells. It was paralleled by lymphopenia in naïve CD4+ T-cell compartment and increase in the frequency of effector memory T-cells, and these changes were more pronounced in active LN.

Conclusions. B-cell memory compartment in LN is deficient in NSM cells and during active disease it is further skewed towards SM and exhausted memory phenotypes, most likely as a cause of chronic antigenic stimulation. Parallel changes in T-helper cell subsets suggest a similar mechanism of SLE-related lymphopenia for both B-cell and T-cell compartment.

(Folia Histochem Cytobiol. 2016, Vol. 54, No. 1, 32–41)

Key words: systemic lupus erythematosus; lupus nephritis; immune memory; B-cells; T-cells; flow cytometry

Introduction

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with B-cell hyper-reactivity, immune complex deposition, and organ damage. Lupus nephritis (LN) develops in ~50% SLE patients, representing the main cause of morbidity and mortality [1, 2]. The significance of self-reacting B-cells in the pathogenesis of LN is supported by a strong causal link between autoantibodies against double stranded DNA (dsDNA) and renal involvement [3, 4]. Additionally, rise in the titer of anti-dsDNA antibodies occurs years before the clinical onset of proliferative LN [5, 6]. It has been suggested that autoimmune inflammation results from repeated stimulation of autoreactive memory T- and B-cells, and subsequent effector responses mediated in part by circulating autoantibodies.

During primary immune response to T-cell dependent (TD) antigens naïve B-cells receive signals from T-helper cells and proliferate rapidly forming germinal centers (GC) in lymphoid tissues. Many of responding B-cells undergo somatic hypermutation and class switching [7]. Memory B-cells generated during GC reaction can be recognized by surface expression of CD27, and are classified as switched memory cells (SM; CD27+IgD+), or non-switched (i.e. IgM+) memory cells (NSM; CD27+IgD+) [8].
During secondary antigen exposure SM B-cells proliferate rapidly and differentiate into antibody secreting cells, while NSM cells are able to reinitiate GC reaction and replenish SM fraction [9, 10]. Because B-cell response to nuclear auto-antigens requires T-cell help, formation of pathogenetic autoantibodies in SLE (e.g. anti-dsDNA) follows the same rules [11]. As a consequence, in all SLE patients a pool of autoreactive memory B- and T-cells is steadily generated. It has been hypothesized that continuous presence toautoantigens favors differentiation of effector memory (EM) T-cells, which mount a pathogenic inflammatory response upon re-exposure to self-antigens [12]. Similarly to other memory cells, they are long-lived and difficult to eliminate, thus pose a considerable therapeutic challenge [13].

Lymphocyte phenotyping in SLE patients revealed expansion of CD27+ memory B-cells with parallel decline in naïve compartment, but little is known if they are intrinsic or develop secondarily to disease-related inflammation [14–16]. Interestingly, memory B-cells in lupus patients often display ‘double negative’ (i.e. CD27-IgD-) phenotype and correlate with renal involvement [17, 18]. Additionally, several groups reported on marked decline in the frequency of CD27+ IgD+B-cells (NSM) mostly in patients with active disease [18–20]. B-cell lymphopenia is another typical feature of SLE, but less is known if it affects all B-cell subsets, and whether it is associated with similar abnormalities in T-cell compartment. Therefore in this study we aimed to analyze subsets of circulating B-cells in LN patients, in search for potential markers associated with disease activity. Additionally, we compared changes in B-cell and T-cell subsets depending on SLE-related lymphopenia.

Material and methods

Characteristics of the patients. Blood samples were taken from 34 systemic lupus erythematosus (SLE) patients with renal involvement, and 23 control subjects (apparently healthy, with negative laboratory tests for antinuclear and antiphospholipid autoantibodies). SLE was diagnosed based on updated criteria of the American College of Rheumatology [21]. LN was confirmed by renal biopsy and classified according to International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria [22] as class II (3%), III (15%), IV (56%) or V (8%). In 6 patients (18%) LN was diagnosed based on overt renal symptoms (proteinuria, active urinary sediment) during lupus flare. We enrolled 16 LN patients with disease exacerbation (active-LN, SLE Disease Activity Index [SLEDAI] > 6, urine protein > 1 g/day or > 2-fold increase with active urinary sediment) and 18 patients in remission (inactive-LN, SLEDAI ≤ 6, urine protein < 1 and normal urinary sediment) [23]. All but one active-LN patients had additional SLE symptoms: hematologic (88%, mostly lymphopenia), joint symptoms (50%), skin lesions (50%), and pleuritis (19%). LN patients were not treated with biological agents targeting B-cells (e.g. rituximab). Additionally, they were not treated with cyclophosphamide in the preceding 6 months. The clinical and laboratory characteristics of LN patients are summarized in Table 1. The study was approved by the Ethics Committee of the Jagiellonian University and informed written consent was obtained from all participants.

Flow cytometry. Aliquots of EDTA anticoagulated blood were stained with a mixture of monoclonal antibodies (all from BD Biosciences, Franklin Lakes, NJ, USA) for detection of CD19+ B-cell (anti-CD45, CD3, CD19, CD21, CD27, IgD; gating strategy shown in Figures 1A, B) and T-cell memory subpopulations (anti-CD45, CD3, CD4, CD8, CD45RA, CD45RO, CCR7). Samples were fixed with FACS lysing solution (BD Biosciences), washed and analyzed in FACS Canto II flow cytometer (BD Biosciences). Based on differential expression of surface markers the following B-cell subsets were identified: immature/early-transitional (I/T, CD27-IgD+CD21low), late-transitional/naïve (CD27-IgD+CD21+), non-switched memory (NSM, CD27+IgD+), resting class-switched memory (SM, CD27+IgD-CD21+), activated SM (CD27+IgD-CD21low), and double-negative (CD27-IgD-) exhausted memory (ExM) as summarized in Figure 1C [8, 16, 23, 25]. Using T-cell panel we identified four subsets within CD4+ or CD8+ gate: naïve (CD45RA+CD45RO-CCR7+), central memory (Tcm, CD45RA-CD45RO+CCR7+), effector memory (Tem, CD45RA-CD45RO+CCR7+), and effector memory CD45RA+ (TemRA, CD45RA+CD45RO-CCR7-) [26, 27].

Statistical methods. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA, USA). Data is presented as medians and 25–75 quartile ranges if not otherwise stated. Differences between two groups were determined by a Mann-Whitney U test. Differences between at least three groups were determined by ANOVA or Kruskal-Wallis test if justified. Spearman’s rank sum test was used to analyze correlation coefficients. P value < 0.05 was considered significant.

Results

Decreased frequency of non-switched memory B-cells and signs of B-cell exhaustion in LN

The phenotypic characteristics of the analyzed B-cell subsets have been shown in Figure 1C. There was a large variability in the percentage of CD19+ B-cells in LN patients, with no difference in comparison with control group. B-cell counts were significantly lower in LN patients both with active and inactive disease.
(Figure 1D). LN patients showed high variability in the distribution of main B-cell subsets, which was more evident in patients with the active disease (Figure 1E). The percentage of early-transitional B-cells (CD27-IgD+CD21low) was increased in the active LN (median 6.5% of CD19+) as compared with inactive LN (3.0%, \( P < 0.05 \)) and control (2.1%, \( P < 0.01 \)) groups (Figure 1F). In all patients with active LN, and in majority (n = 15, 83%) of patients with inactive disease, we observed a marked decrease (median 2.4% and 2.3%, respectively) in the percentage of NSM B-cells (Figure 1E, F) as compared with control subjects (13.4%). This was a characteristic feature of B-cell memory compartment, distinctive to SLE (Figure 1G). Additionally, we observed increased frequency of activated SM cells in active LN (median 12.6%) as compared with other groups (inactive LN — 6.0%, \( P < 0.05 \), control — 2.5%, \( P < 0.01 \)).

Moreover, B-cell compartment in LN patients had signs of memory exhaustion, as evidenced (Figure 1E, F) by increased percentage of double negative (CD27-IgD-) CD19+ B-cells (median 6.8% in active- and 9.9% in inactive-LN vs. 2.4% in control group, \( P < 0.01 \)). Next, we compared absolute counts of B-cells in order to identify changes associated with SLE-induced lymphopenia. As shown in Figure 1H, there was a strong (> 10-fold) decrease in the number of NSM B-cells in LN patients (independently of the activity of the disease) as compared with control group, but we also found a significant, though less pronounced decrease in the count of naïve and resting SM B-cells.

### Subsets of CD21low B-cells correlate with LN activity
Overall, there was a strong association of B-cells with decreased expression of CD21 (comprised of early-transitional and activated/exhausted B-cells) with the activity of the disease (Figure 2A). In particular, we showed a correlation (Figure 2B, C) between the percentage of immature/early-transitional B-cells and various markers of SLE activity, e.g. SLEDAI.

#### Table 1. Characteristics of the subjects studied

<table>
<thead>
<tr>
<th></th>
<th>Active LN (n = 16)</th>
<th>Inactive LN (n = 18)</th>
<th>Control group (n = 23)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex (Females, %)</strong></td>
<td>12 (75%)</td>
<td>15 (83%)</td>
<td>18 (78%)</td>
</tr>
<tr>
<td><strong>Symptoms (in history)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skin</strong></td>
<td>15 (94%)</td>
<td>14 (78%)</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>Joints</strong></td>
<td>16 (100%)</td>
<td>15 (83%)</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>Pleuropericarditis</strong></td>
<td>6 (38%)</td>
<td>8 (44%)</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>Neurologic</strong></td>
<td>1 (6%)</td>
<td>2 (11%)</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>Hematologic</strong></td>
<td>16 (100%)</td>
<td>16 (89%)</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>LN class II/III/IV/V (unknown)</strong></td>
<td>1/2/9/2(2)</td>
<td>0/3/10/1(4)</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>SLEDAI (score)</strong></td>
<td>21.5 [14–24]**</td>
<td>2 [0–4]</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>Anti-dsDNA (titer)</strong></td>
<td>480 [160–2560]**</td>
<td>40 [10–160]</td>
<td>none</td>
</tr>
<tr>
<td><strong>Proteinuria (g/day)</strong></td>
<td>2.4 [1.7–5.2]**</td>
<td>0.1 [0.06–0.39]</td>
<td>n.a.</td>
</tr>
<tr>
<td><strong>Creatinine (serum, μmol/L)</strong></td>
<td>69.5 [65.2–91.7]</td>
<td>66 [60.2–80.5]</td>
<td>71 [65–79]</td>
</tr>
<tr>
<td><strong>C3c (mg/dL)</strong></td>
<td>0.545 [0.44–0.785]<strong>,</strong></td>
<td>1.035 [0.790–1.185]*</td>
<td>1.15 [0.963–1.41]</td>
</tr>
<tr>
<td><strong>CRP (mg/L)</strong></td>
<td>17.1 [9.1–25.8]<strong>,</strong></td>
<td>1.7 [0.6–7.7]*</td>
<td>0.7 [0.3–2.8]</td>
</tr>
<tr>
<td><strong>Lymphocytes (•10³/uL)</strong></td>
<td>0.67 [0.37–1.26]**</td>
<td>0.89 [0.65–1.38]**</td>
<td>1.82 [1.61–2.21]</td>
</tr>
<tr>
<td><strong>Current systemic GCS (mg/d)</strong></td>
<td>8 [4–16]*</td>
<td>4 [0–4]</td>
<td>none</td>
</tr>
<tr>
<td><strong>Cumulative CTX dose (g)</strong></td>
<td>0 [0–8.6]**</td>
<td>9.5 [6.1–26.2]</td>
<td>n.a.</td>
</tr>
</tbody>
</table>

1According to International Society of Nephrology/Renal Pathology Society criteria [22]. Data are presented as medians [25–75 quartiles]. \(*\ P < 0.05\) and \(*\ P < 0.01\), respectively, in comparison with control group; \(**\ P < 0.05\) and \(*\ P < 0.01\), respectively, in comparison with Inactive LN.

Abbreviations: ANA — anti-nuclear antibodies; C3c — complement component C3c; CRP — C-reactive protein; CTX — cyclophosphamide; GCS — glucocorticoids (recounted for methylprednisolone); LN — lupus nephritis; SLEDAI — SLE disease activity index; WBC — white blood cells.
Figure 1. Subsets of memory B-cells in systemic lupus erythematosus (SLE) patients and control subjects. A. Flow cytometry (FC) gating strategy used to identify major subsets of CD19+ B-cells (details in the methods section, abbreviations explained in C). Dot-plots represent FC data of a control individual (K20); B. Similar gating strategy applied to FC data of lupus nephritis (LN) patient (P04); C. Diagram summarizing main subtypes of circulating CD19+ B-cells identified on the basis of the expression of CD21, CD27 and IgD; D. Percentage and counts of peripheral blood CD19+ B-cells in all studied groups. Horizontal bars represent medians; E. Percentages of different CD19+ B-cell subsets shown separately for each individual (data for CD21low NSM cells were also included).

\((R = 0.48)\), dsDNA \((R = 0.61)\) and complement components (e.g. \(C4, R = -0.48\)). Additionally, percentage of activated SM B-cells showed weak association with SLEDAI score \((R = 0.37)\) and peripheral blood lymphocyte count \((R = -0.35)\). As expected, absolute counts of naïve, NSM and resting SM B-cells also correlated with clinical markers of the disease (not shown). Interestingly, activated SM B-cells (but not
Figure 1. (cont.) Subsets of memory B-cells in SLE patients and control subjects. F. Differences in the percentage values of B-cells between all studied groups. Horizontal bars represent medians. *P < 0.05, **P < 0.01; G. ROC curves of the prediction of a given disease phenotype based on NSM (% of CD19+) data. Individual AUC (area under the curve) values are plotted next to each representative data-set; H. Fold changes in the number of analyzed B-cell subsets (RC — relative to control group, e.g. value 0.1 means 10-fold decrease, data presented as means and 95% CI). Naïve, NSM and resting-SM B-cells were significantly decreased (**P < 0.01) in both active- and inactive-LN patients as compared with controls.

other B-cell types) correlated weakly with daily urine protein excretion (R = 0.36) and urine sediment erythrocytes (R = 0.51). Percentage of memory B-cell subsets was comparable in LN-patients stratified based on renal biopsy status (data not shown).

Increased percentage of effector memory T-cells in LN
The decrease in absolute number of T-cells was comparable in active- and inactive-LN (median 514 and 700 cells/μL, respectively, vs. 1388 in control subjects, P < 0.01) and affected mostly CD4+ T-cells (237 and 409 cells/μL in LN groups vs. 923 in controls, P < 0.01) resulting in lower percentage of CD4+ T-cell in LN (median 37% of total lymphocytes in all LN patients vs. 47% in controls) and decreased CD4/CD8 ratio (1.01 and 1.67 in active- and inactive-LN vs. 2.37 in controls, P < 0.01). Additional staining for CD45RA, CD45RO and CCR7 (Figure 3A) allowed for identification of naïve and memory T-cell subsets (Figure 3B). The main feature of T-cell compartment in LN was a significant decrease in the percentage of naïve T-helper cells (36.8% in LN vs. 48.0% in control group, P < 0.05) and increase in the percentage of TEM subset (29.7% vs. 14.5%, respectively, P < 0.01), with no difference between active and inactive disease (Figure 3C). The frequency of CD8+ T-cell subsets did not change considerably in LN (Figure 3C). Further analysis showed significant decrease in the absolute count of naïve and TCM cells (primarily CD4+) in LN as compared with control subjects, which was more prominent in the active disease (Figure 3D). Comparison of B-cell and T-cell memory fractions revealed a weak correlation of the percentage of CD4+ TEM with both NSM (r = −0.42) and ExM B-cells (r = 0.48). Not surprisingly, there was a considerable correlation between the magnitude in the decrease of absolute counts of CD4+ T and B fractions, which was most prominent in case of naïve CD4+ and NSM B-cells (Figure 3F).
Figure 2. Association of B-cell subsets with clinical and laboratory parameters of lupus nephritis (LN). A. Percentage of CD21low B-cells in the studied groups. **P < 0.01; B. Correlation matrix showing significant (P < 0.05, bold) associations between the main subsets of B-cells (abbreviations explained in Fig. 1C) and selected markers of active SLE (data from the whole SLE group). CRP — C-reactive protein, C3c — complement component 3Cc, C4 — complement component C4, PBL — peripheral blood lymphocytes (count), CTX — cyclophosphamide (cumulative dose); C. Scatter-plots showing the correlations of the percentage of immature/transitional B-cells with serum levels of C3c and SLEDAI score

Discussion

Earlier studies showed specific changes in B-cell compartment in SLE, though data on the association between various memory B-cells and disease activity are inconsistent [18, 28, 29]. To address this point we quantified different subsets of B-cells in patients with inactive LN and during disease exacerbations, and also checked if they are paralleled by similar changes within T-cell memory compartment. We defined main subsets of B-cells based on multicolor flow cytometry panel, including staining for CD27 (memory marker), surface-IgD and CD21 (complement receptor CR2, a component of BCR co-receptor complex), which allowed to distinguish switched and non-switched memory B-cells and additionally CD21low immature and activated B-cells.

Decreased frequency of NSM B-cells was the most prominent feature of LN in the current study. This alteration was observed in all LN patients with disease exacerbation and in a majority (83%) of patients in remission. Our data is in line with previous reports showing deficiency in CD27+IgD+ cells in SLE [18, 19], though in contrast to earlier study [18], we did not see any association of B-cell NSM percentage with disease activity status. The subset of NSM B-cells has been implicated in immune responses against T-cell independent antigens, however recent studies confirmed their role as a long-lasting memory to T-cell dependent antigens involved in reconstitution of switched memory pool upon antigen restimulation [10]. Changes in NSM fraction were accompanied by increased percentage of immature/early-transitional B-cells and activated SM cells, both
Figure 3. Memory T-cell subsets in systemic lupus erythematosus (SLE). A. Flow cytometry dot-plots (whole blood gated on CD4+ or CD8+ T-cells) showing major subsets of memory T-cells. CM — central memory, EM — effector memory, EMRA — effector memory CD45RA+; B. Simplified diagram showing the main stages of differentiation of memory T-cells and their candidate surface markers (based on [16, 22]); C. Percentages (within CD4+ [left] or CD8+ [right] T-cells) of memory subsets in control subjects and lupus nephritis (LN) patients. Horizontal bars represent mean values. *$P<0.05$, **$P<0.01$; D. Graph showing the relative decrease in the absolute counts of CD8+ and CD4+ memory subsets in LN patients as compared with control group (RC — relative to controls). Whiskers represent 95% CI. *$P<0.01$ in comparison with controls. #$P<0.05$ between active and inactive LN; E. Correlation matrix shows Pearson r coefficients in comparisons of major memory subsets of CD19+ B-cells (abbreviations explained in the Fig. 1C) and CD4+ T-cells in LN group. Significant ($P<0.05$) associations are marked in bold font; F. Correlation between fold decrease (in comparison with mean value in the control group, RC — relative to control) in NSM B-cells and naive CD4+ T-cells in LN patients.
subsets defined as CD21\textsuperscript{low}. During development of humoral response the loss of CD21 expression in CD27+/ memory B-cells occurs during their activation and differentiation towards antibody secreting cells [8, 16, 23]. Nevertheless, systemic accumulation of B-cells with CD27+/CD21\textsuperscript{low} phenotype, e.g. during chronic viral infections, is also considered as a sign of aberrant B-cell activation and dysfunction within the memory compartment [21, 30]. In this study we observed very similar B-cell changes in LN patients. The fraction of activated SM B-cells (CD27+CD21\textsuperscript{low}) was \~3-fold higher in patients with active LN as compared with control group. In line with previous reports [17, 18, 29], we also observed increased frequency of double negative (i.e. CD27-IgD-) B-cells in patients with LN. This fraction represents class-switched memory cells that lost CD27 expression, which are also markedly expanded during chronic infections, and resemble tissue-like exhausted memory B-cells [23, 32]. These results suggest altogether that reduction in NSM B-cells is most likely a consequence of facilitated class switch of IgM+ memory cells and further differentiation towards SM-activated and exhausted memory phenotypes. This was further confirmed by analysis of absolute counts of B-cells. As it turned out, SLE related lymphopenia affected mostly naïve and NSM B-cells, but again, with no evident association with disease activity status. Moreover, despite clear increase in the percentage of immature/early-transitional cells, there was no change in their absolute count. This observation confirms that bone marrow production of B-cells is not disturbed in SLE, as has been suggested previously [33]. Instead, our results support the concept on preferential depletion of IgM+ memory pool in LN due to their constant activation (repeated exposure to self-antigens) and continuous replenishing of SM-pool. However other explanations, e.g. abnormal selection processes or diminished susceptibility of particular memory B-cells to immunosuppressive drugs, are still possible. But autoreactive B-cells are only a tiny fraction of all memory cells, so why the whole compartment is changed? Some hints came from recent study, showing that various neutrophil-derived proinflammatory mediators facilitate differentiation of IgD+/CD27+ memory B-cells and IgG class switch [10]. Neutrophils participate in the pathogenesis of LN, and both neutrophil derived cytokines (e.g. CCL2) and markers of neutrophil activation (extracellular traps) correlate with the activity of glomerulonephritis and dsDNA titers [34, 35]. This implies that B-cell memory compartment in LN may also be shaped by innate immunity mediators released at the site of autoimmune inflammation. Because class switching and B-cell activation are under strict control of T-helper cells we further explored if similar changes of immune memory developed also in T-cell compartment.

A characteristic feature of systemic autoimmunity is constant exposure to tissue antigens, which favors differentiation of long-lasting T\textsubscript{EM} cells with well-developed effector functions [12]. In SLE this phenomenon may be associated with impaired immunosuppression, due to persistently lower numbers of regulatory T-cells or their impaired function [36, 37]. Similarly to previous report [38], we observed lower frequency of naïve CD4+ T-cells and increased percentage of T\textsubscript{EM} fraction in both active- and inactive-LN. Additionally, we showed that SLE-related lymphopenia affected mostly naïve CD4+ lymphocytes. The reasons for decreased CD4+ lymphocyte count in SLE are, however, poorly understood. It may result from higher susceptibility of T-cells to apoptosis due to diminished expression of complement regulatory proteins or defective Fas/Fas-ligand system [39]. The depletion of lymphocytes may also be linked with anti-lymphocyte antibodies, which are detected in \~50% of SLE patients presenting with lymphopenia [40]. Interestingly, we observed comparable decrease (\~10-fold) in absolute counts of antigen inexperienced T-cells and NSM B-cells. We also showed a correlation between the percentage of naïve fractions of B-cells and CD4+ T-cells, as well as between their mature subsets. This observation suggests that chronic antigenic stimulation and facilitated shift towards T\textsubscript{EM} may also contribute to lymphopenia in T-cell compartment. It is also tempting to speculate that decline in one compartment, e.g. in CD4+ T-cells, may trigger similar changes in the other. It has been shown that transient depletion of B cells can potently influence reactivation and maintenance of pathogen specific CD4+ T cells [40]. However, there are only scarce data on possible interaction between CD4+ lymphopenia and the concomitant quantitative changes in B cell subsets [23, 42].

The presented data highlight similarities in changes of B-cell and CD4+ T-cell subsets in LN patients, including deficiency in naïve (or non-switched) cells in all SLE patients and relative increase in effector memory (or exhausted) subsets during overt disease. LN-related changes in B-cell memory compartment, particularly the decline in NSM B-cells, may result from chronic antigenic stimulation and facilitated differentiation towards mature memory phenotypes, though it does not exclude possible intrinsic abnormalities related to abnormal selection processes or varying sensitivity to immunosuppressants. Marked decrease in the percentage of circulating CD27+/IgD+ memory B-cells was a typical signature of LN, while
the increase in CD21low B-cells could be used as additional laboratory marker of active disease. Whether B-cell memory subsets are skewed to the same extent in other SLE manifestations, or their diagnostic potential in SLE remains to be further studied.

Acknowledgements

This study was supported by National Science Center, Poland, grant number N402 627940.

References


4. Devarajan P, Chen Z. Autoimmune effector memory T cells: in other SLE manifestations, or their diagnostic potential in SLE remains to be further studied.


15. Dörner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythemato


31. Decyre JF, Côté G, Néron S. A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes...


Submitted: 14 September, 2015
Accepted after reviews: 3 April, 2016
Available as AoP: 14 April, 2016